Equities

Lattice Biologics Ltd

LBL.H:NEX

Lattice Biologics Ltd

Actions
  • Price (CAD)0.04
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 03 2021.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.

  • Revenue in CAD (TTM)2.13m
  • Net income in CAD-1.30m
  • Incorporated--
  • Employees--
  • Location
    Lattice Biologics Ltd512 E. Madison Ave. Suite A1BELGRADE 59714United StatesUSA
  • Phone+1 (406) 570-2658
  • Fax+1 (480) 563-0810
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lattice Biologics Ltd2.13m-1.30m4.13m--------1.93-0.0103-0.01030.01680.00111.013.838.70---61.69------28.53---61.08--0.00-1.020.00--12.60---46.52------
SQI Diagnostics Inc3.04m-19.13m6.11m55.00------2.01-0.0483-0.04830.0077-0.0350.2863.233.91---179.74-147.99---264.3310.9748.25-628.52-400.280.1193-3.0324.07--783.5352.95-75.46--42.57--
Cloud DX Inc1.52m-10.63m10.75m--------7.09-0.1261-0.12610.0182-0.15190.5870.3246.20---411.46------89.60---701.01--0.1158-2.47----49.05--5.68------
Evome Medical Technologies Inc62.63m-15.60m11.57m195.00--4.22--0.1847-0.2094-0.20940.80690.04741.254.378.85321,166.50-31.11---95.79--35.98---24.91--0.2864-2.090.8605--------------
Hapbee Technologies Inc2.15m-4.89m12.07m--------5.62-0.055-0.0550.0235-0.02570.61422.3735.18---139.73---858.81--62.27---227.49--0.0993------5.32--45.59------
Aurora Spine Corp19.87m-2.30m17.69m13.00--2.67--0.8904-0.0329-0.03290.28160.09361.311.913.80---15.20-16.00-21.27-22.2356.5546.65-11.57-11.761.51-8.080.4077---2.4010.83-11.93--10.36--
Data as of Jun 03 2021. Currency figures normalised to Lattice Biologics Ltd's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.